Emergency Preparedness and Response

FDA/DoD Work Plan

Initial Work Plan for Products Relevant to the Department of Defense (DoD)


On January 16, 2018, the U.S. Food and Drug Administration and the Department of Defense announced the launch of a joint program to prioritize the efficient development of safe and effective medical products intended for deployed American military personnel. The framework for the program was put in place through Public Law 115-92, which authorized DoD to request, and FDA to provide, assistance to expedite development and the FDA’s review of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel.

Utilizing these expanded authorities, the FDA will work closely with DoD’s Office of Health Affairs to better understand the military’s medical needs for deployed personnel; give the highest level of attention to and expedite its review of priority DoD medical products in a manner similar to products under the breakthrough designation program; provide ongoing technical advice to DoD to aid in the rapid development and manufacturing of medical products for use by the military; and, take a closer look at products currently under development to determine opportunities to expedite their availability.
 

 

Page Last Updated: 03/05/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English